Alteogen filed an amended registration statement (amendment No. 1) for its merger with its subsidiary Alteogen Biologics on October 19, 2026.

Alteogen first filed a registration statement for its merger with its subsidiary Alteogen Biologics on October 14, 2026 and then voluntarily amended it on October 19, 2026. The company said the amendment changes the shareholder briefing session from scheduled to held and adds detailed answers to shareholder questions. The company said the merger ratio is 0.1679581 Alteogen shares for each Alteogen Biologics share, and the actual number of new shares to be issued in the merger is 600,477 shares.

1. 01

   This amendment is a voluntary correction of the registration statement first filed on October 14, 2026, and it revises the disclosure on shareholder communications and the shareholder briefing session.

2. 02

   The company said it will allot Alteogen shares at 0.1679581 shares for each Alteogen Biologics share.

3. 03

   The company said the intrinsic value of Alteogen Biologics was calculated at about KRW 433.9 billion (KRW 43,895 per share).

4. 04

   The previous filing listed the shareholder briefing sessions as scheduled, while the amended filing lists them as held on October 14, 2026 for Alteogen Biologics and on October 15 for Alteogen.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Merger price per share (Alteogen)

KRW 261,345

Merger ratio

1 : 0.1679581

Actual number of new shares to be issued

600,477 shares

Value of new shares issued in the merger (based on Alteogen merger price per share)

KRW 156.9 billion

Size relative to Alteogen market capitalization

About 0.86%

Filing facts

Filing type

Merger

Report name

[Amended] Securities Registration Statement (Merger)

Filed

Oct 19, 2026

Receipt number

20261019000334